Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 October 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Healing in children with IBD treated with thalidomide

A study in the latest issue of the Clinical Gastroenterology & Hepatology examines endoscopic and histologic healing in children with inflammatory bowel diseases treated with thalidomide.

News image

Mucosal healing, determined by endoscopic evaluation, is one of the most important prognostic markers for patients with inflammatory bowel diseases.

Findings from histologic evaluation, however, could complement findings from endoscopy in assessing mucosal responses to treatment.

Dr Marzia Lazzerini and colleagues analyzed long-term results of children treated with thalidomide to determine the association between clinical response and histology and endoscopy findings.

The team collected data from 2 multicenter trials of 70 children with refractory Crohn’s disease (CD) or ulcerative colitis (UC) given thalidomide or placebo.

Clinical remission and clinical response at 8 weeks were defined as a pediatric CD activity index scores 10 points or lower and a decrease of at least 50% from baseline, respectively, for patients with CD.

The researchers defined clinical remission and clinical response at 8 weeks as a pediatric UC activity index score below 10, and a decrease of at least 20 points from baseline, respectively, for patients with UC.

The team observed clinical remission in 60% at Week 8
Clinical Gastroenterology & Hepatology

Patients with a clinical response to 8 weeks’ treatment with thalidomide underwent endoscopic examination with biopsy collection at study weeks 12 and 52.

Severity of inflammation in patients with UC was assessed by Mayo score and in patients with CD by 4-grade system.

The research team assessed biopsies for signs of active inflammation, erosion or ulceration, and crypt abscesses and assigned a histologic score.

The team observed clinical remission in 60%, and clinical response in 64% at Week 8.

At Week 52, a total of 54% of patients were still in clinical remission or still had a clinical response.

The researchers observed that 41% of patients had mucosal healing, defined as complete healing of erosions or ulcerations, and 28% had histologic healing, defined as complete absence of markers of inflammation.

Of patients with clinical remission or clinical response, 75% also had mucosal healing and 53% also had histologic healing.

The team noted that the probability of achieving mucosal healing decreased significantly with increasing values of erythrocyte sedimentation rate.

Dr Lazzerini's team concludes, "In a long-term analysis of data from 2 clinical trials of pediatric patients with CD or UC, 52 weeks’ treatment with thalidomide led to clinical remission in 54% of patients with ileocolonic or colonic disease.

"Of these patients, 75% had mucosal healing and 53% also had histologic healing."

"Further studies are needed to determine how thalidomide therapy affects long-term progression of inflammatory bowel diseases."

Clin Gastroenterol Hepatol 2017: 15(9): 1382–1389.e1
01 September 2017

Go to top of page Email this page Email this page to a colleague

 18 October 2017 
Predicting recurrence after curative rectal cancer surgery
 18 October 2017 
Prebiotic and changes in the human gut microbiota
 18 October 2017 
Hep E seroprevalence and hemodialysis
 17 October 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 17 October 2017 
Medication nonadherence and health care costs
 17 October 2017 
Asthma and IBD development
 16 October 2017 
Colorectal cancer screening and postpolypectomy surveillance colonoscopy
 16 October 2017 
Continuity of care after colorectal surgery
 16 October 2017 
Breastfeeding and the risk of IBD
 13 October 2017 
Treating patients with HCV and severe renal impairment
 13 October 2017 
Blood pressure management during abdominal surgery
 13 October 2017 
Food elimination diets for eosinophilic esophagitis
 12 October 2017 
Global recurrence of H. pylori
 12 October 2017 
Colonoscopy in an organized colorectal cancer screening program 
 12 October 2017 
Predicting advanced fibrosis in chronic hepatitis B
 11 October 2017 
Fecal microbiota transplantation for ulcerative colitis
 11 October 2017 
Sexual functioning in Hep C
 11 October 2017 
Ulcerative proctitis in pediatric-onset UC
 10 October 2017 
Quality standards in upper gastrointestinal endoscopy
 10 October 2017 
Eosinophilic esophagitis and swallowed topical corticosteroids
 10 October 2017 
Follow-up of positive results on fecal blood tests
 09 October 2017 
Diverticulitis and emergency department burden
 09 October 2017 
Clostridium difficile infection after ileostomy reversal
 09 October 2017 
Global recurrence rate of H. pylori
 06 October 2017 
Predicting nontreatment for Hep C
 06 October 2017 
Cow's milk–based formula and development of celiac disease
 06 October 2017 
Propofol for outpatient colonoscopy
 05 October 2017 
Pediatric candidates on the transplant wait list
 05 October 2017 
Incidence of sepsis in the USA
 05 October 2017 
Quality of life after chemoradiation in rectal cancer
 04 October 2017 
Peptic ulcer disease diagnosed in acute upper endoscopy
 04 October 2017 
Clinical practice guidelines in colon cancer
 04 October 2017 
Rural residence and risk of IBD
 03 October 2017 
Antibody tests and detecting celiac disease
 03 October 2017 
Novel candidate risk genes for IBD
 03 October 2017 
Environmental factors and IBD
 02 October 2017 
Full publication of Gastroenerology abstracts
 02 October 2017 
Interferon-free therapy in advanced liver disease
 02 October 2017 
Burden of NAFLD with advanced fibrosis in the USA
 29 September 2017 
Inpatient Gastroenterology training experience
 29 September 2017 
Proteomic analysis of IBD
 28 September 2017 
Social networking-based discussion group by ERCP doctors
 28 September 2017 
Incidence of biopsy-verified celiac disease
 27 September 2017 
Predictors of nonadherence in IBD
 27 September 2017 
Hep C treatment in the era of direct-acting anti-viral agents
 27 September 2017 
Function of trypsin-3 in IBS
 26 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 26 September 2017 
Factors associated with the risk of metachronous gastric neoplasm
 26 September 2017 
Treatment of hyperactive delirium in advanced cancer
 25 September 2017 
Lenalidomide for advanced liver cancer
 25 September 2017 
Silibinin nanoparticles inhibit HCV infection
 22 September 2017 
Perforation after colonic endoscopic mucosal resection
 22 September 2017 
Medical management and colectomy rates
 22 September 2017 
MRI for liver metastatic colorectal cancer
 21 September 2017 
Adenomatous colorectal polyps in young cancer survivors
 21 September 2017 
Predicting mucosal healing in treated celiac disease patients
 21 September 2017 
Antireflux surgery and recurrence of GERD
 20 September 2017 
Rifaximin and spontaneous bacterial peritonitis in cirrhosis
 20 September 2017 
Omega-3 PUFA and colorectal cancer survival
 20 September 2017 
Beta-blockers and cardiopulmonary exercise testing in liver disease

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us